Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration (Details)

v3.24.3
Fair Value Measurements - Financial Assets and Liabilities Carried at FV on Recurring Basis and Exarafenib Milestone Contingent Consideration (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Assets:    
Exarafenib milestone asset (Note 4) $ 3,125  
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,125  
Fair Value, Recurring    
Assets:    
Cash equivalents 138,032 $ 28,352
Exarafenib milestone asset (Note 4) 3,125  
Equity securities 785 161
Total financial assets 141,942 28,513
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,125  
Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value   1,000
Total financial liabilities 3,125  
Fair Value, Recurring | Money market funds    
Assets:    
Cash equivalents 112,895 28,352
Fair Value, Recurring | U.S. treasury bills    
Assets:    
Cash equivalents 25,137  
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Cash equivalents 138,032 28,352
Equity securities 785 161
Total financial assets 138,817 28,513
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Cash equivalents 112,895 28,352
Fair Value, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. treasury bills    
Assets:    
Cash equivalents 25,137  
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Assets:    
Exarafenib milestone asset (Note 4) 3,125  
Total financial assets 3,125  
Liabilities:    
Exarafenib milestone contingent consideration (Note 4) 3,125  
Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value   $ 1,000
Total financial liabilities $ 3,125